. 2019 Jan 1;10(3):716–720. doi: 10.7150/jca.28246

Table 1.

Research summaries comparing the effects of cannabinoids and placebo in CCA.

Study ID or RCT number	Study method	Human subjects	Interventional group	Control group	Follow up (d)	Outcomes
Brisbois 2011³⁰	parallel-group RCTs	advanced cancer patients	THC (2.5 mg, n = 24)	Placebo (n = 22)	19	Appetite, AEs, QOL
Johnson 2010²⁸	parallel-group RCTs	advanced cancer patients	THC:CBD extract (2.7 mg THC and 2.5 mg CBD, n = 60), THC extract (2.7 mg THC, n = 58)	Placebo (n = 59)	14	Appetite, AEs, QOL
Strasser 2006³¹	parallel-group RCTs	advanced cancer patients	CE (standardized for 2.5 mg THC and 1 mg cannabidiol, n = 95) or THC (2.5 mg, n = 100)	Placebo (n = 48)	42	Body weight, appetite, AEs, QOL
NCT03245658	Crossover Assignment	pancreatic cancer patients	THC 25mg/ml and CBD 50mg/ml (n=32)	N/A	4 weeks	Energy and protein intake, lean body mass, appetite, mortality, QOL
NCT02802540	parallel-group RCTs	Non-small cell lung cancer (NSCLC) patients	1 mg nabilone	placebo	8 weeks	Anorexia, percentage weight loss, body mass index, subjective global assessment, QOL, AEs
Jatoi 2002³²	Crossover Assignment	advanced cancer patients	(1) megestrol acetate 800 mg/d plus placebo, (2) dronabinol 2.5 mg twice a day plus placebo, or (3) both agents	N/A	4 weeks	weight, appetite, AEs, QOL
Cote 2016³³	parallel-group RCTs	squamous cell carcinoma patients	0.5 mg nabilone	placebo	4 weeks	QOL, pain, nausea, appetite, AEs